Stability of an extemporaneously compounded levothyroxine sodium oral liquid

American Journal of Health-System Pharmacy

Volumn 53, Issue 10, 1996, Pages 1157-1161

  Boulton, David W ^a   Fawcett, J Paul ^a   Woods, David J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Compounding; Formulations; Incompatibilities; Levothyroxine sodium; Liquids; Methylparaben; Powders; Preservatives; Stability; Storage; Tablets; Temperature; Thyroid drugs

Indexed keywords

DRUG PRESERVATIVE; GLYCEROL; LEVOTHYROXINE SODIUM; METHYL PARABEN; POLYETHYLENE;

ARTICLE; CONTAINER; DRUG DEGRADATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID; ORAL DRUG ADMINISTRATION; POWDER; PRIORITY JOURNAL; TABLET;

EID: 0029940520     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.10.1157     Document Type: Article

References (7)

1. Paediatric formulary. 3rd ed. London: Guy's and St. Thomas' Hospital Trust; 1994:160.
2. AHFS drug information 95. McEvoy GK, ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 1995: 2219.
3. The Merck index. 9th ed. Windholz M, ed. Rahway, NJ: Merck; 1976:1116-7.
4. Won CM. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm Res. 1992; 9:131-7.
5. Sansom LN, ed. Australian Pharmaceutical Formulary and handbook. 15th ed. Netley, Australia: Pharmaceutical Society of Australia; 1992:434.
6. Garnick RL, Burt GF, Long DA et al. High-performance liquid Chromatographic assay for sodium levothyroxine in tablet formulations: content uniformity applications. J Pharm Sci. 1984; 73.75-7.
7. British Pharmacopoeia. Vol 2. London: British Pharmacopoeia Commission; 1993:A187.